Department of Respiratory Medicine, The Affiliated Suqian Hospital of Xuzhou Medical University, Suqian, 223800 Jiangsu, China.
Department of Pathology, The Affiliated Suqian Hospital of Xuzhou Medical University, Suqian, 223800 Jiangsu, China.
Comput Math Methods Med. 2022 Jul 8;2022:2923998. doi: 10.1155/2022/2923998. eCollection 2022.
It was to explore the correlation between regulatory T cells (Treg)/T helper cell 17 (Thl7) and the efficacy of receiving a programmed death protein-1 (PD-1) monoclonal antibody (mAb) in patients with advanced non-small-cell lung cancer (NSCLC) complicated with chronic obstructive pulmonary disease (COPD).
The research subjects were 82 patients who were clinically evaluated and treated in the Respiratory Department of Suqian Hospital connected with Xuzhou Medical University from January to December 2021. All of the patients were given PD-1 immunotherapy, and 50 healthy people were chosen as the control group. Classification was carried out according to tumor type and tumor stage. The levels of Th17 and Treg/Th17 in the peripheral blood of patients with different tumor-node-metastasis (TNM) stages and different types were compared, and the immune function, lung function (forced expiratory volume in one second/forced vital capacity (FEV1%/FVC), FEV1%, and FVC), and changes in inflammatory factors were compared before and after treatment. The levels of interleukin (IL)-17, IL-6, tumor necrosis factor (TNF)-, and transforming growth factor (TGF)- were compared between the two groups. The correlation between Th17 cells and Treg cells in the peripheral blood of patients with NSCLC complicated with COPD was analyzed.
After treatment, the levels of IL-17, IL-6, TNF-, and TGF- in patients with NSCLC combined with COPD were notably superior to those in the control group ( < 0.05). The immune function and lung function of the patients were improved after treatment. There were 43 cases of squamous cell carcinoma, 30 cases of adenocarcinoma, and 9 cases of large cell carcinoma. The proportion of Th17 cells to CD4+ T cells in the blood of the three types of patients and the proportion of CD4CD25CD127 regulatory T cells to CD4+ lymphocyte cells in Treg cells showed no considerable difference among the different case types ( > 0.05). No considerable difference was indicated in Treg/Th17 in peripheral blood between stage IIIB and stage IV lung cancer patients ( > 0.05). A positive linear correlation was revealed between Th17 cells and Treg cells in the peripheral blood of patients with NSCLC combined with COPD, = 0.26, = 0.039.
Treg and Th17 cells were shown to be much higher in lung cancer patients with COPD, which could lead to immunosuppression and tumor growth. PD-1 therapy for NSCLC has demonstrated efficacy and can improve patients' immunological state while being extremely safe.
探讨调节性 T 细胞（Treg）/辅助性 T 细胞 17（Th17）与晚期非小细胞肺癌（NSCLC）合并慢性阻塞性肺疾病（COPD）患者接受程序性死亡蛋白-1（PD-1）单克隆抗体（mAb）疗效的相关性。
选取 2021 年 1 月至 12 月在徐州医科大学附属宿迁医院呼吸科进行临床评估和治疗的 82 例患者作为研究对象，所有患者均接受 PD-1 免疫治疗，选择 50 例健康人作为对照组。根据肿瘤类型和肿瘤分期进行分类。比较不同 TNM 分期和不同类型患者外周血中 Th17 和 Treg/Th17 的水平，比较治疗前后免疫功能、肺功能（用力呼气量/用力肺活量（FEV1%/FVC）、FEV1%和 FVC）和炎症因子变化。比较两组患者白细胞介素（IL）-17、IL-6、肿瘤坏死因子（TNF）-和转化生长因子（TGF）-水平。分析 NSCLC 合并 COPD 患者外周血中 Th17 细胞与 Treg 细胞的相关性。
治疗后，合并 COPD 的 NSCLC 患者的 IL-17、IL-6、TNF-和 TGF-水平明显优于对照组（<0.05）。治疗后患者的免疫功能和肺功能均有所改善。有 43 例为鳞癌，30 例为腺癌，9 例为大细胞癌。三种类型患者血液中 Th17 细胞与 CD4+T 细胞的比例和 Treg 细胞中 CD4+CD25+CD127 调节性 T 细胞与 CD4+淋巴细胞的比例在不同病例类型之间无明显差异（>0.05）。ⅢB 期和Ⅳ期肺癌患者外周血中 Treg/Th17 无明显差异（>0.05）。合并 COPD 的 NSCLC 患者外周血中 Th17 细胞与 Treg 细胞呈正线性相关，=0.26，=0.039。
COPD 合并肺癌患者的 Treg 和 Th17 细胞明显升高，可能导致免疫抑制和肿瘤生长。PD-1 治疗 NSCLC 具有疗效，并能改善患者的免疫状态，且安全性极高。
